RxDoctor Payments Data

Shawn Nash, DO

Ophthalmology · Seattle, WANPI 1801203088

Payments from drug & device makers

$2,236in general payments, 2019–2025

Across 83 payments — averaging $26.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$978
  • Sun Pharmaceutical Industries Inc.$242
  • Bausch & Lomb Americas Inc.$239
  • Tarsus Pharmaceuticals, Inc.$132
  • Astellas Pharma Global Development$115
  • Rxsight Inc$104
  • plus $426 from 9 others

What the payments were for

  • Speaking & faculty fees$392%
  • Food & beverage$2,17597%
  • Gifts$211%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,236 in reported general payments places this provider in the 70th percentile of 428 ophthalmology providers in Washington.

See all ophthalmology providers in Washington

Medicare billing

Part B allowed, 2024
$326,757
Medicare patients
562
Services billed
2,625

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine13$8,075
LumiganBimatoprost15$7,934
Prednisolone Acetate106$4,665
Latanoprost464$4,556
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$3,061
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat130$2,419
Timolol Maleate136$1,722
Tobramycin-DexamethasoneTobramycin/Dexamethasone30$1,237
Brimonidine Tartrate67$1,203
Ketorolac Tromethamine31$690
Dorzolamide Hcl27$533
ErythromycinErythromycin Base38$471
Acyclovir23$218
Ofloxacin16$198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$69$16,01028 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 428 ophthalmology providers in Washington.

Other ophthalmology in Seattle

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →